ImaginAb

A look back at 2024 at our highlights... Check out, “Evaluating the immunologically “cold” tumor microenvironment after treatment with immune checkpoint inhibitors utilizing PET imaging of CD4+ and CD8+ T cells in breast cancer models”. Published last June, this collaboration with the University of Alabama at Birmingham, PET radiotracers targeting CD8 and CD4 were used in a murine model of breast cancer to establish a correlation between the changes in CD4+ and CD8+ T-cells, and long-term anti-tumor response to immune checkpoint inhibitors (ICB) in immunologically “cold” tumors. Through advanced PET imaging techniques, this study explores the visualization of distribution activities of CD4+ and CD8+ T-cells during ICB treatment. Read the article here: https://lnkd.in/gcGzCw69 Would you like to learn more? Email info@imaginab.com #BreastCancerResearch #Immunotherapy #PETImaging #CD4 #CD8 #ImaginAb #immunooncology #CD8ImmunoPET 

We continue to be excited about the work our partners do with CD8 ImmunoPET in non-oncology indications. Here is #alookback at this 2024 highlight. Erik Aarntzen and the team at Radboudumc on the published their research report, “Preliminary evidence of localing “CD8+T-cell responses in COVID-19 patients with PET imaging” in the Fronters in Medicine journal this past Spring. Read how CD8 T cells were imaged in this research utilizing CD8 ImmunoPET.  Click here to read: https://lnkd.in/gi_QDQCs Would you like to learn more? Email info@imaginab.com #PETImaging #CD4 #CD8 #Immunotherapy #ImaginAb #immunooncology #CD8 ImmunoPET #biotech #pharma #BIO #PETCT #immunooncology #theranostics #CD8 

We’re taking a look back at some of our 2024 highlights, including our esteemed partners' participation in the development of our lead investigational imaging agent, 89Zr Crefmirlimab Berdoxam (CD8 ImmunoPET™). Last January, Peter Zang and co-authors at the City of Hope were awarded the ASCO Merit Award at this year’s ASCO GU meeting. Check out one of the first award-winning poster of the year here: https://lnkd.in/gyQXueeK Would you like to learn more? Email info@imaginab.com #CD8 #ImaginAb #immunooncology #CD8 ImmunoPET #biotech #pharma  #PETCT #theranostics #CD8 #cancer #oncology

Happy Holidays from ImaginAb! As we wrap up another incredible year, we want to extend our heartfelt gratitude to our amazing staff, dedicated partners, and wonderful audience. Your support and hard work have been the driving force behind our success. To our staff, thank you for your unwavering commitment and passion. Your efforts have made this year truly remarkable. To our partners, we appreciate your collaboration and trust. Together, we've achieved great milestones and look forward to many more. To our supporters and followers, thank you for your continued support and engagement. You inspire us to continue to innovate and strive for excellence every day. Wishing you all a joyous holiday season filled with love, laughter, and happiness during this holiday season Warmest wishes, Team ImaginAb #ImaginAb #CD8ImmunoPET #immunooncology #pharma #biotech #radiopharmaceutical #PETCT #nuclearmedicine

Congratulations to BriaCell Therapeutics Corp. on their recent poster presentation at this year's San Antonio Breast Cancer Symposium highlighting the infiltration of cancer-fighting immune cells into tumors, using CD8 ImmunoPET imaging agent! Check it out! #CancerResearch #BreastCancerSymposium #BriaCell #CD8ImmunoPET

Calmen Tihansky and Suzanne Bissonnette had a fantastic time attending the ASH Annual Meeting in San Diego, CA. Suzanne states, “It was great connecting with innovative biotech companies and engaging with numerous poster presenters who are advancing groundbreaking research. We’re inspired by the collaborations and conversations driving progress in oncology.” #ASH2024 #Hematology #InnovationInMedicine #ImaginAb #CD8ImmunoPET #RPT #biotech #theranostics #immunoonocology  #research #clinicaltrials #Pharmaceuticals #NuclearMedicine #Innovation

We’re thrilled to announce that Michael Ferris will be attending this year’s ESMO - European Society for Medical Oncology Immuno-Oncology (I/O) Conference in Geneva, Switzerland! Mike is looking forward to connecting with fellow experts, sharing insights, and exploring the latest advancements in immuno-oncology. It’s a fantastic opportunity to engage with the global oncology community and contribute to the future of cancer treatment. If you’re attending, don’t miss the chance to connect with Mike and discuss potential collaborations. Connect with Mike in Geneva by scheduling a meeting here: https://lnkd.in/gXtRCCJz #ESMOIO2024 #ImmunoOncology #CancerResearch #ImaginAb #CD8ImmunoPET #RPT #biotech #theranostics #immunoonocology  #research #clinicaltrials #Pharmaceuticals #NuclearMedicine #Innovation

Happy Thanksgiving from ImaginAb! This Thanksgiving, we are grateful for our incredible team, partners, and the amazing advancements we’ve made together in the field of immuno-oncology. Wishing everyone a joyful and safe holiday filled with gratitude, warmth, and happiness. Thank you for being a part of our journey! #HappyThanksgiving #ImaginAb #Gratitude #Thankful #ImmunoOncology #Teamwork #TeamImaginAb #Innovation #ImaginAb #CD8ImmunoPET #RPT #biotech #PETCT #research #clinicaltrials #Radiopharmaceuticals #RPT #Pharmaceuticals #theranostics

Our sales team is thrilled to announce that we will be attending this year’s American Society of Hematology's (ASH) 65th Annual Meeting in San Diego, CA! We are looking forward to engaging with fellow professionals, sharing our latest research, and exploring the newest advancements in hematology. It’s a fantastic opportunity to connect, learn, and contribute to the future of hematology. If you’re attending, we’d love to meet up and discuss how we can collaborate with you on your clinical trials. Schedule a meeting and meet us https://lnkd.in/gQmY2tFt #ASH2024 #Hematology #InnovationInMedicine #ImaginAb #CD8ImmunoPET #RPT #biotech #theranostics #immunoonocology  #research #clinicaltrials #Pharmaceuticals #NuclearMedicine #Innovation

Read our latest article: https://lnkd.in/gKgvJdvc Accurately assessing immune response in cancer patients undergoing immunotherapy is crucial for evaluating treatment efficacy and predicting outcomes. See how CD8+ T cells and the Immunoscore are two key biomarkers that are gaining attention in immunooncology. #ImmunoOncology #CancerTreatment #InnovationInHealthcare #CD8ImmunoPET #immunooncology #immunotherapy #oncology #medicalresearch